来自Agathis dammara的化合物通过增强葡萄糖吸收来施加低血糖活性:,烯和其他物质
Zhe-Wei Yu1,2, Bang-Ping Cai3, Su-Zhi Xie4
1School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, China.
Natural products and bioprospecting
|March 22, 2024
概括
研究人员从Agathis dammara中分离出新型化合物,其中一些显示出显著的低血糖活性. 这些化合物增强斑马鱼的葡萄糖吸收,为糖尿病研究提供了潜力.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- Agathis dammara是一种因其丰富的化学成分而闻名的植物物种.
- 自然产品是治疗化合物的宝贵来源.
- 了解Agathis dammara的化学多样性和生物活性可以导致新的药物发现.
研究的目的:
- 从Agathis dammara中分离和描述新型化合物.
- 为了研究孤立化合物的低血糖活性.
- 阐明表现出低血糖效应的化合物的作用机制.
主要方法:
- 使用色谱技术分离化合物.
- 使用高分辨率电喷射电离质谱法 (HR-ESIMS) 和1D/2D核磁共振 (NMR) 光谱法阐明结构.
- 通过电子循环二元化 (ECD) 激发性性方法确定绝对配置.
- 在斑马鱼模型中进行体内低血糖活性评估.
主要成果:
- 他们分离了两种新的kaurane diterpenes,12种已知的lignans,一种triterpene以及另外两种化合物.
- 化合物5,11和14在斑马鱼中表现出显著的低血糖活性.
- 作用机制包括增强斑马鱼的葡萄糖吸收.
结论:
- 阿加蒂斯·达马拉 (Agathis dammara) 是各种化学结构的来源,包括新型二烯.
- 化合物5,11和14具有显著的低血糖特性.
- 这些已识别的化合物可以通过向葡萄糖吸收途径,作为开发新型抗糖尿病药物的线索.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196


